Deal Watch: Teva and Regeneron Announce Fasinumab Collaboration

more+
less-

On September 20, Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced an agreement to develop and commercialize fasinumab, an investigational NGF antibody currently under development by Regeneron as a treatment for osteoarthritis and chronic low back pain.   The press release states Teva and Regeneron will collaborate globally, excluding Japan, Korea, and 9 other Asian countries that are part of a previous fasinumab collaboration between Regeneron and Mitsubishi Tanabe Pharma.

According to the announcement, under the terms of the agreement, Teva will make an initial upfront payment of $250 million to Regeneron, and the companies will share equally in the ongoing R&D costs (estimated at approximately $1 billion) and the value of the commercialized product.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

more+
less-

Goodwin on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×